



HIV Clinical Program Overview

Merck has been with the HIV community since the early days of the epidemic, with more than 35 years of research and discovery leading to scientific breakthroughs that have helped change HIV treatment.

We are pushing the bounds of science to research areas of unmet medical need in HIV prevention and treatment, and our investigational HIV pipeline includes:

- **Islatravir (MK-8591):** an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation with other HIV medicines for the treatment of HIV-1
 - **MK-8591A:** an oral once-daily combination of doravirine and islatravir (DOR/ISL) in Phase 3 development
 - **MK-8591D:** an oral once-weekly combination of islatravir and Gilead’s lenacapavir in Phase 3 development
- **MK-8527:** a novel oral once-monthly NRTTI candidate that is in Phase 2 development for HIV-1 pre-exposure prophylaxis (PrEP)

Treatment Development Program	
Daily Oral Treatment Options	islatravir / doravirine Phase 3
Weekly Oral Treatment Options	islatravir / lenacapavir* Phase 3

PrEP** Development Program	
Monthly Oral PrEP Options	MK-8527 Phase 2

*Collaboration with Gilead
**Pre-exposure Prophylaxis

Development Program	Study Number & Link
Doravirine / Islatravir	
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)	NCT05631093
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)	NCT05630755
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)	NCT05705349
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)	NCT05766501
Open-label, Follow-up of Doravirine/Islatravir for Participants With Human Immunodeficiency Virus -1 (HIV-1) Infection (MK-8591A-033)	NCT04776252
Islatravir / Lenacapavir (in collaboration with Gilead)	
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV	NCT05052996 (Gilead is study sponsor)
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)	NCT06630286 (Gilead is study sponsor)
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2)	NCT06630299 (Gilead is study sponsor)
MK-8527	
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)	NCT05494736
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)	NCT06045507